2016 American Transplant Congress
Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.
Surgery, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.
Purpose: For living-donor liver transplantation (LDLT), there has been a tendency to accept extended criteria in comparison with deceased-donor liver transplantation (DDLT). However, HCC recurrence…2016 American Transplant Congress
Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.
Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…2016 American Transplant Congress
Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?
Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not…2016 American Transplant Congress
Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation.
Background Predicting risk for recurrence of hepatocellular carcinoma (HCC) following living donor liver transplantation (LDLT) is clinically important.Methods We performed a retrospective study for assessment…2015 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to early allograft loss. A…2015 American Transplant Congress
The use of Donation After Cardiac Death Liver Allografts does not increase Recurrence of Hepatocellular Carcinoma
Transplant, Mayo Clinic, Jacksonville, FL.
Background: Previous studies examining the Scientific Registry of Transplant Recipients (SRTR) database for liver transplantation (LT) have demonstrated inferior survival for hepatocellular carcinoma (HCC) recipients…2015 American Transplant Congress
Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation
Background and Objective: Elevated plasma fibrinogen (FBG) level is associated with tumor progression and poor patient outcomes in several cancers. The aim of this study…2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…2015 American Transplant Congress
Predictors of Time to Recurrence and Mortality Associated With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Transplantation, UCLA, Los Angeles, CA.
Background: While recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) portends a poor prognosis, adjuvant therapy may prolong survival. We sought to identify factors that…2015 American Transplant Congress
Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities
General Surgery, Houston Methodist Hospital, Houston, TX.
AIM:Treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) can help downstage tumors prior to orthotopic liver transplantation (OLT); however, there is a risk of…
American Transplant Congress abstracts